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Introduction
The contributors to this symposium represent six
countries and eight different disciplines, and all have
had a major interest in the specific clinical and patho-
logical entity of analgesic nephropathy. These papers
on experimental and human pathology, pharmacolo-
gy, and epidemiology provide a background for the
clinical studies from the United States, the United
Kingdom, Canada, Australia, and Sweden.
It seems likely that analgesic nephropathy
emerged as a new disease entity at about the middle
of this century. Zollinger and Spuhler [1] recognized
in 1950 that chronic interstitial nephritis was appear-
ing with increased frequency at autopsy and noted
the associated papillary necrosis and abuse of Sari-
don®a. Gloor [2] documented the increase in inter-
stitial nephritis in Switzerland in more detail. He
showed that whereas renal papillary necrosis was
found in only 2.7% of cases of chronic interstitial
nephritis studied at autopsy between 1938 and 1942,
it was present in 57% of such cases between 1958 and
1962.
About a decade after Zollinger and Spühler's first
report, analgesic nephropathy was being recognized
as a frequent clinical, radiological, and autopsy find-
ing in Scandinavia [3—6] and in Australia [7—9].
Ninety-two patients with analgesic nephropathy pre-
sented at the Royal Melbourne Hospital between
1959 and 1962, and in addition to renal disease, these
patients often had peptic ulceration, psychiatric in-
stability, anemia, hypertension, and myocardial
infarction [9]—the cardinal features of the analgesic
syndrome, which have been further discussed by
several authors in this Symposium.
Small groups of cases have been reported from
Great Britain [10, 11], the United States [12], and
Canada [13], but there seems little doubt that a real
difference in prevalence exists between different
geographic areas. Schreiner, by an enquiry among
physicians, was able to establish only 15 definite
cases of analgesic nephropathy in the United States
up to 1962 [42], which contrasts with the 92 cases
presented at one hospital in Australia in the four years
1959 through 1962 [9]. Autopsy surveys also reflect
this difference; thus, only 0.2% of 11,000 autopsies at
Johns Hopkins Hospital between 1947 and 1961
showed renal papillary necrosis, and Davies, Kenne-
dy, and Roberts [14] found renal papillary necrosis in
only 0.16% of 18,866 necropsies in Liverpool
between 1961 and 1967. Studies in Australia are in
striking contrast and have shown that renal papillary
necrosis is present in between 3.7% and 20% of
autopsies carried out in major hospitals over the past
fifteen years [15—20]. In Switzerland, where analge-
sic nephropathy was first recognized, the autopsy
incidence has remained between 1.1 and 1.3% over
the past 20 years [21]. The reason for these differ-
ences in geographic distribution is one of the most
fascinating unanswered questions in this field.
Within Australia, both regular analgesic consump-
tion and end-stage renal failure due to renal papillary
necrosis are noticeably less in some States than in
others (Stewart, this issue). Those States with the
highest analgesic consumption also show the highest
rate (per million of the population) of patients with
renal failure due to renal papillary necrosis. Climatic
differences between the different States have been
suggested as a factor contributing to the greater prev-
alence of papillary necrosis in the warmer northern
States [22]. In Victoria, which has the greatest varia-
tion in temperature between summer and winter,
renal papillary necrosis was found to be significantly
more frequent as an autopsy finding in the summer
months than in the winter months [17]. Not all
patients who consume large quantities of analgesics
develop renal papillary necrosis, and dehydration
associated with hot climatic conditions could be one
of the factors predisposing to episodes of papillary
necrosis, any one of which may prove fatal. It seems
unlikely that climatic variations could explain more
than a small part of the remarkable geographic differ-
ences in autopsy incidence of renal papillary necrosis
quoted above. The pattern of analgesic use or abuse
together with differences in the compounds and mix-
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tures taken in different countries are more likely to
explain differences in prevalence.
Within the United Kingdom (Murray, this issue)
and the United States (Murray and Goldberg, this
issue), the number of cases of analgesic nephropathy
in different areas also varies. In the United King-
dom, there is a striking preponderance of cases in the
Glasgow area, whereas in the United States the
Southeastern States show the highest number of cas-
es. In Glasgow, Murray (this issue) found that the
favorite preparation of those who took analgesics
daily without medical advice was "Askit," a prepa-
ration which differs from other British analgesics in
that it is a powder and contains more caffeine.
"Askit" was taken with excessive frequency for
mood-altering properties, while other preparations
such as aspirin or paracetamol were likely to be
taken infrequently for appropriate reasons. This situ-
ation in Glasgow seems to closely mimic the Austra-
lian situation. In Australia, Nanra et a! (this issue)
quote a reference dating back to 1907 which stated
that "what the drink habit is among men in Australia,
the headache powder is among women." In Austral-
ia, two-thirds of patients with analgesic nephropathy
take "Bex" or "Vincents" powders, each having a
high caffeine content (Nanra et al, this issue). The
psychological dependence, as well as increasing dos-
age to control analgesic-induced side effects, are
characteristic in Australia as in Western Scotland
(Murray, this issue). One way in which the extent of
the problem in different countries has been assessed
is in terms of the percentage of patients with end-
stage renal failure in whom analgesic nephropathy is
the cause. In spite of the inherent inaccuracies in this
estimation, which depends upon age and other crite-
ria for acceptance for dialysis, it is interesting that
the relative ratio of patients in Europe and in Aus-
tralia presenting with "end-stage" renal failure due
to analgesic nephropathy is the same as the ratio
found in autopsy studies. There is a 10:1 ratio both in
the autopsy studies quoted above and in the dialysis
registry figures. In Europe, 2.5% of patients accept-
ed for dialysis have analgesic nephropathy [26],
whereas in Australia as many as 25% of new patients
admitted to dialysis programs in one year have had
analgesic nephropathy (Australian Kidney Founda-
tion Dialysis Registry Data).
One of the more serious hazards of long term
analgesic abuse, namely malignancy within the uri-
nary tract, is discussed in this symposium by Bengts-
son, Johansson, and Angervall from Sweden.
Of the many topics covered in this symposium,
two controversial questions warrant further com-
ment. When it was first suggested that renal papillary
necrosis was the primary lesion and that the cortical
changes were secondary [27, 28], European patholo-
gists found this concept very difficult to accept and
regarded the papillary necrosis as a secondary
lesion. Gloor (this issue), reviewing his extensive
experience over twenty years in Switzerland, states
unequivocally that the cortical changes of chronic
interstitial nephritis are secondary, and there is much
to support this in the literature [29—34]. Just when it
seems that a consensus might be reached on this
question, Molland (this issue) presents new experi-
mental data, which conflicts with that of Hardy [35],
and which shows that the development of cortical
lesions does not depend upon the presence of papil-
lary necrosis. This question, like many others in the
experimental field, requires further investigation, as
stressed by Shelley (this issue).
The most controversial problem concerns the
analgesic agent or agents responsible for the devel-
opment of analgesic nephropathy. No one would
want to reintroduce phenacetin, the sales of which
have declined dramatically due to voluntary and leg-
islative pressures in various countries in recent
years. Unfortunately, however, the withdrawal of
phenacetin from Vincents Powders in Australia in
1967 has not, in any way, altered the clinical features
or course in patients taking Vincents Powders (con-
taining aspirin, salicylamide, and caffeine) when
these are compared with those of patients taking Bex
Powders (which until 1976 contained aspirin, phena-
cetin, and caffeine). The usual rapid improvement in
renal function which follows withdrawal of all anal-
gesics [35, 36] was not observed in patients who
continued to take aspirin, salicylamide, and caffeine
in the form of Vincents Powders. (Nanra et al, this
issue). Experimental findings cannot be applied
directly to man, but both phenacetin and its major
metabolite acetaminophen (paracetamol) have been
proved to be relatively nontoxic in animals, whereas
combinations of aspirin and phenacetin produce pap-
illary necrosis and cortical lesions resembling those
seen in analgesic nephropathy [37—39]. Aspirin alone
produces papillary necrosis and renal damage (Mol-
land, this issue) in a far more predictable manner
than does phenacetin alone, and a wide range of
chemically unrelated anti-inflammatory agents will
also produce papillary necrosis. It has been suggest-
ed that the common factor which may account for
this effect is medullary prostaglandin depletion and,
consequently, reduction in medullary blood flow
[40]. Molland's findings (this issue) add some sup-
port to this view. She also illustrates with light and
electron microscopy that with aspirin administration
alone, lesions in the vasa recta occur, similar to
those described previously in rats receiving aspirin
and phenacetin [41].
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A recent recommendation by the National Health
& Medical Research Council of Australia could pro-
vide an answer to this long debated question. This
body has made recommendations which, if imple-
mented, would lead to the disappearance of all the
commonly abused analgesic mixtures and com-
pounds. Implementation of these recommendations
lies in the hands of the States, and it seems likely that
some States will accept the recommendations and
others will not. Prospective studies of the effect of
this legislation on analgesic nephropathy in different
States of Australia may at last provide an answer to
the long standing controversy about the drug or
drugs which lead to analgesic nephropathy in man.
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